Intratumoral administration of IFN-β gene therapy showed great efficacy in promoting rejection of GL-261 tumors in mice [20] and therapeutic concentrations of IFN-β sensitize glioma cells including glioma stem-like cells to irradiation and temozolomide [21,22]. This evidence concerns the gene IFNB1 and glioma.